SCHEMBL722248

SCHEMBL722248

c1ccc(-c2cncc(-c3ccccc3)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.62
MKNK1 Q9BUB5 2/20 0.61
MKNK2 Q9HBH9 2/20 0.61
CHRNA7 P36544 1/20 0.57
CYP11B1 P15538 4/20 0.55
CYP11B2 P19099 4/20 0.55
ALDH1A1 P00352 2/20 0.53
NOTUM Q6P988 1/20 0.52
GABRA1 P14867 1/20 0.50
GABRG2 P18507 1/20 0.50
GABRB3 P28472 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50
CYP19A1 P11511 1/20 0.50
FDPS P14324 2/20 0.47
CHRNA3 P32297 2/20 0.47
CHRNB4 P30926 1/20 0.47
CYP2A6 P11509 2/20 0.46
CHRNB2 P17787 1/20 0.46
SMO Q99835 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21692173 1.00 ATM (0.62) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL12076750 0.95 MKNK1 (0.57) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL5533122 0.92 MKNK1 (0.55) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL15496379 0.88 CYP2A6 (0.68) ATMMKNK1MKNK2CYP11B1CYP11B2
SCHEMBL18745741 0.86 HSD17B10 (0.65) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL18212414 0.86 MKNK1 (0.59) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL12345157 0.86 MKNK1 (0.50) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL28594491 0.86 MKNK1 (0.50) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL12339167 0.86 MKNK1 (0.55) ATMMKNK1MKNK2CHRNA7CYP11B1
SCHEMBL5331238 0.84 ATM (0.63) ATMMKNK1MKNK2CHRNA7CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118027957-A Method for manufacturing long afterglow photon glass by long afterglow molecular microsphere and ink-jet printing and application thereof 中山大学 2024-05-14 CN claimed
CN-113979927-B Method for preparing fluorescent molecules through intermolecular self-assembly 常州大学 2023-07-25 CN claimed
CN-116284510-A Metallocene catalyst, preparation method and application thereof 万华化学集团股份有限公司 2023-06-23 CN claimed
CN-113979927-A Method for preparing fluorescent molecule through intermolecular self-assembly 常州大学 2022-01-28 CN claimed
WO-2026090602-A1 PIGMENTED RESIN AND CATALYST COMPOSITIONS MATERIA, INC. (US) 2026-04-30 WO disclosed
EP-3110862-B1 ADHESION PROMOTER COMPOSITIONS FOR CYCLIC OLEFIN RESIN COMPOSITIONS ExxonMobil Product Solutions Company (US) 2026-04-01 EP disclosed
EP-4683900-A2 ROMP AND THERMAL INSULATION COMPOSITIONS AND MATERIALS AND USE THEREOF Materia, Inc. (US) 2026-01-28 EP disclosed
WO-2025245037-A1 CYCLIC OLEFIN COMPOSITIONS, ROMP COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF MATERIA, INC. (US) 2025-11-27 WO disclosed
EP-4194092-B1 SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS UMICORE AG & CO KG (DE) 2025-10-22 EP disclosed
EP-4581071-A1 METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE Forschungszentrum Jülich GmbH (DE) 2025-07-09 EP disclosed
EP-2970522-B1 IN-MOLD COATING OF ROMP POLYMERS MATERIA INC (US) 2025-05-21 EP disclosed
EP-3013886-B1 THERMAL INSULATION MATERIA INC (US) 2025-03-26 EP disclosed
WO-2004013198-A2 SYNTHESIS OF MACROCYCLIC POLYMERS BY RING INSERTION POLYMERIZATION OF CYCLIC OLEFIN MONOMERS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2004-02-12 WO disclosed
US-20030236427-A1 Cross-metathesis of olefins directly substituted with an electron-withdrawing group using transition metal carbene catalysts NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-12-25 US disclosed
JP-2003331646-A ION CONDUCTIVE COMPOSITION TOKUYAMA CORP 2003-11-21 JP disclosed
WO-2003087167-A2 CROSS-METATHESIS OF OLEFINS DIRECTLY SUBSTITUTED WITH AN ELECTRON-WITHDRAWING GROUP USING TRANSITION METAL CARBENE CATALYSTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2003-10-23 WO disclosed
US-5438143-A Process for the preparation of substituted pyridines via 1-aza-1,3-butadienes and the 1-aza-1,3-butadiene intermediates DSM N.V. (NL) 1995-08-01 US disclosed
EP-0543880-B1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDINES VIA 1-AZA-1,3-BUTADIENES AND THE 1-AZA-1,3-BUTADIENE INTERMEDIATES DSM NV (NL) 1995-04-19 EP disclosed
EP-0543880-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDINES VIA 1-AZA-1,3-BUTADIENES AND THE 1-AZA-1,3-BUTADIENE INTERMEDIATES. DSM NV (NL) 1993-06-02 EP disclosed
WO-1992002505-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDINES VIA 1-AZA-1,3-BUTADIENES AND THE 1-AZA-1,3-BUTADIENE INTERMEDIATES DSM N.V. (NL) 1992-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236427-A1 Cross-metathesis of olefins directly substituted with an electron-withdrawing group using transition metal carbene catalysts OXER1, DUOX2, AOC2 ATM 1627/4885MKNK1 2014/4885MKNK2 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.